

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

**September 18, 2008**

-----  
**ORDER GRANTING CONFIDENTIAL TREATMENT  
UNDER THE SECURITIES EXCHANGE ACT OF 1934**

**Nucryst Pharmaceuticals Corp.  
File No. 0-51686 - CF#21120**

-----

**Nucryst Pharmaceuticals Corp. submitted an application under rule 24b-2 requesting confidential treatment for information it excluded from the Exhibits to a Form 8-K/A filed on November 6, 2007.**

**Based on representations by Nucryst Pharmaceuticals Corp. that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibits will not be released to the public for the time periods specified:**

<b>Exhibit 99.1</b>	<b>through October 28, 2015</b>
<b>Exhibit 99.2</b>	<b>through October 28, 2015</b>

**For the Commission, by the Division of Corporation Finance, pursuant to delegated authority:**

**Christian Windsor  
Special Counsel**